发布求助
文献互助 智能选刊 最新文献

Nature Reviews Clinical Oncology最新文献

筛选
英文 中文
On the cusp of targeted therapy for cancer cachexia — what clinical benefits might we promise our patients? 癌症恶病质靶向疗法即将问世--我们能为患者带来哪些临床益处？
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-11-05 DOI: 10.1038/s41571-024-00964-1
Vickie E. Baracos
{"title":"On the cusp of targeted therapy for cancer cachexia — what clinical benefits might we promise our patients?","authors":"Vickie E. Baracos","doi":"10.1038/s41571-024-00964-1","DOIUrl":"10.1038/s41571-024-00964-1","url":null,"abstract":"A number of therapeutics that target mediators of signalling in the hypothalamic and brainstem regions that control appetite, ingestive behaviour, satiety, nausea and vomiting are starting to move the needle on cancer cachexia. However, clarification of meaningful clinical benefits for patients and the primary end points that should support regulatory approval of cachexia treatments is needed.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 1","pages":"8-9"},"PeriodicalIF":81.1,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142580740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia 驾驭 B 细胞淋巴瘤和慢性淋巴细胞白血病 BTK 靶向疗法的变化格局
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-11-01 DOI: 10.1038/s41571-024-00956-1
Michele D. Stanchina, Skye Montoya, Alexey V. Danilov, Jorge J. Castillo, Alvaro J. Alencar, Julio C. Chavez, Chan Y. Cheah, Carlos Chiattone, Yucai Wang, Meghan Thompson, Paolo Ghia, Justin Taylor, Juan Pablo Alderuccio
{"title":"Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia","authors":"Michele D. Stanchina, Skye Montoya, Alexey V. Danilov, Jorge J. Castillo, Alvaro J. Alencar, Julio C. Chavez, Chan Y. Cheah, Carlos Chiattone, Yucai Wang, Meghan Thompson, Paolo Ghia, Justin Taylor, Juan Pablo Alderuccio","doi":"10.1038/s41571-024-00956-1","DOIUrl":"10.1038/s41571-024-00956-1","url":null,"abstract":"The B cell receptor (BCR) signalling pathway has an integral role in the pathogenesis of many B cell malignancies, including chronic lymphocytic leukaemia, mantle cell lymphoma, diffuse large B cell lymphoma and Waldenström macroglobulinaemia. Bruton tyrosine kinase (BTK) is a key node mediating signal transduction downstream of the BCR. The advent of BTK inhibitors has revolutionized the treatment landscape of B cell malignancies, with these agents often replacing highly intensive and toxic chemoimmunotherapy regimens as the standard of care. In this Review, we discuss the pivotal trials that have led to the approval of various covalent BTK inhibitors, the current treatment indications for these agents and mechanisms of resistance. In addition, we discuss novel BTK-targeted therapies, including covalent, as well as non-covalent, BTK inhibitors, BTK degraders and combination doublet and triplet regimens, to provide insights on the best current treatment paradigms in the frontline setting and at disease relapse. In several B cell malignancies, BTK is a crucial mediator of oncogenic signalling pathways and inhibitors of this kinase have substantially improved patient outcomes. This Review discusses the currently approved indications for covalent and non-covalent BTK inhibitors, as well as mechanisms of resistance, and novel BTK-targeted agents and treatment strategies that have the potential to further improve outcomes.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 12","pages":"867-887"},"PeriodicalIF":81.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142562057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress 作者更正：美国抗癌疗法的高昂成本：挑战、机遇与进步
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-30 DOI: 10.1038/s41571-024-00958-z
Shelley A. Jazowski, Rahul K. Nayak, Stacie B. Dusetzina
{"title":"Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress","authors":"Shelley A. Jazowski, Rahul K. Nayak, Stacie B. Dusetzina","doi":"10.1038/s41571-024-00958-z","DOIUrl":"10.1038/s41571-024-00958-z","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 12","pages":"903-903"},"PeriodicalIF":81.1,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41571-024-00958-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142536890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cadonilimab is effective and safe in recurrent cervical cancer 卡多尼单抗对复发性宫颈癌有效且安全
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-25 DOI: 10.1038/s41571-024-00962-3
Diana Romero
{"title":"Cadonilimab is effective and safe in recurrent cervical cancer","authors":"Diana Romero","doi":"10.1038/s41571-024-00962-3","DOIUrl":"10.1038/s41571-024-00962-3","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 1","pages":"2-2"},"PeriodicalIF":81.1,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142489804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’ 回复 "NALIRIFOX在转移性胰腺癌一线治疗中的应用：NAPOLI 3以外的证据
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-25 DOI: 10.1038/s41571-024-00953-4
Christopher Nevala-Plagemann, Thierry Conroy, Ignacio Garrido-Laguna
{"title":"Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’","authors":"Christopher Nevala-Plagemann, Thierry Conroy, Ignacio Garrido-Laguna","doi":"10.1038/s41571-024-00953-4","DOIUrl":"10.1038/s41571-024-00953-4","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 12","pages":"902-902"},"PeriodicalIF":81.1,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41571-024-00953-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3 NALIRIFOX 在转移性胰腺癌一线治疗中的应用：NAPOLI 3 之外的证据
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-25 DOI: 10.1038/s41571-024-00952-5
Zev A. Wainberg, Eileen M. O’Reilly
{"title":"NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3","authors":"Zev A. Wainberg, Eileen M. O’Reilly","doi":"10.1038/s41571-024-00952-5","DOIUrl":"10.1038/s41571-024-00952-5","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 12","pages":"900-901"},"PeriodicalIF":81.1,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41571-024-00952-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lack of benefit from extended lymphadenectomy in muscle-invasive bladder cancer 肌肉浸润性膀胱癌的扩大淋巴结切除术缺乏益处
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-23 DOI: 10.1038/s41571-024-00961-4
Diana Romero
{"title":"Lack of benefit from extended lymphadenectomy in muscle-invasive bladder cancer","authors":"Diana Romero","doi":"10.1038/s41571-024-00961-4","DOIUrl":"10.1038/s41571-024-00961-4","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 12","pages":"838-838"},"PeriodicalIF":81.1,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The TOPGEAR trial — is chemoradiotherapy no longer a component of multidisciplinary care for gastric cancer? TOPGEAR 试验--化放疗是否不再是胃癌多学科治疗的组成部分？
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-21 DOI: 10.1038/s41571-024-00960-5
Brian Badgwell
{"title":"The TOPGEAR trial — is chemoradiotherapy no longer a component of multidisciplinary care for gastric cancer?","authors":"Brian Badgwell","doi":"10.1038/s41571-024-00960-5","DOIUrl":"10.1038/s41571-024-00960-5","url":null,"abstract":"Adjuvant chemoradiotherapy has a proven survival benefit for patients undergoing upfront resection of gastric cancer compared with surgery alone. Now, data from the TOPGEAR trial demonstrate that adding radiotherapy to standard-of-care perioperative chemotherapy offers no additional survival benefit. I discuss the implications for treatment and future research.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 1","pages":"4-5"},"PeriodicalIF":81.1,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142451853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MRI-based stratification reduces the risk of overdiagnosis of prostate cancer 基于磁共振成像的分层可降低前列腺癌过度诊断的风险
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-16 DOI: 10.1038/s41571-024-00957-0
Peter Sidaway
{"title":"MRI-based stratification reduces the risk of overdiagnosis of prostate cancer","authors":"Peter Sidaway","doi":"10.1038/s41571-024-00957-0","DOIUrl":"10.1038/s41571-024-00957-0","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 12","pages":"838-838"},"PeriodicalIF":81.1,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142439733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author Correction: Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response 作者更正：针对dMMR和pMMR结直肠癌的新辅助免疫疗法：治疗策略和反应的假定生物标志物
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2024-10-07 DOI: 10.1038/s41571-024-00955-2
Christopher J. M. Williams, Allyson M. Peddle, Pashtoon M. Kasi, Jenny F. Seligmann, Campbell S. Roxburgh, Gary W. Middleton, Sabine Tejpar
{"title":"Author Correction: Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response","authors":"Christopher J. M. Williams, Allyson M. Peddle, Pashtoon M. Kasi, Jenny F. Seligmann, Campbell S. Roxburgh, Gary W. Middleton, Sabine Tejpar","doi":"10.1038/s41571-024-00955-2","DOIUrl":"10.1038/s41571-024-00955-2","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 12","pages":"903-903"},"PeriodicalIF":81.1,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41571-024-00955-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142383729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信